HRP20210891T1 - Liječenje bolesti presatka protiv primatelja u pacijenata s transplantacijom - Google Patents

Liječenje bolesti presatka protiv primatelja u pacijenata s transplantacijom Download PDF

Info

Publication number
HRP20210891T1
HRP20210891T1 HRP20210891TT HRP20210891T HRP20210891T1 HR P20210891 T1 HRP20210891 T1 HR P20210891T1 HR P20210891T T HRP20210891T T HR P20210891TT HR P20210891 T HRP20210891 T HR P20210891T HR P20210891 T1 HRP20210891 T1 HR P20210891T1
Authority
HR
Croatia
Prior art keywords
compound
conditioning
use according
day
days
Prior art date
Application number
HRP20210891TT
Other languages
English (en)
Croatian (hr)
Inventor
Peter Gergely
Kazuhiko Kuriyama
Original Assignee
Priothera Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Priothera Limited filed Critical Priothera Limited
Publication of HRP20210891T1 publication Critical patent/HRP20210891T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01B—SOIL WORKING IN AGRICULTURE OR FORESTRY; PARTS, DETAILS, OR ACCESSORIES OF AGRICULTURAL MACHINES OR IMPLEMENTS, IN GENERAL
    • A01B1/00—Hand tools
    • A01B1/02—Spades; Shovels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Environmental Sciences (AREA)
  • Soil Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20210891TT 2013-02-20 2014-02-18 Liječenje bolesti presatka protiv primatelja u pacijenata s transplantacijom HRP20210891T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361766830P 2013-02-20 2013-02-20
PCT/IB2014/059067 WO2014128611A1 (en) 2013-02-20 2014-02-18 Treatment of graft versus host disease in transplant patients
EP14708330.7A EP2958624B1 (en) 2013-02-20 2014-02-18 Treatment of graft versus host disease in transplant patients

Publications (1)

Publication Number Publication Date
HRP20210891T1 true HRP20210891T1 (hr) 2021-07-23

Family

ID=50236228

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210891TT HRP20210891T1 (hr) 2013-02-20 2014-02-18 Liječenje bolesti presatka protiv primatelja u pacijenata s transplantacijom

Country Status (23)

Country Link
US (2) US20160000811A1 (enExample)
EP (1) EP2958624B1 (enExample)
JP (2) JP6441822B2 (enExample)
KR (1) KR102165514B1 (enExample)
CN (1) CN105007981B (enExample)
AU (1) AU2014220377B2 (enExample)
BR (1) BR112015019197A2 (enExample)
CA (1) CA2898565C (enExample)
CY (1) CY1124191T1 (enExample)
DK (1) DK2958624T3 (enExample)
EA (1) EA030783B1 (enExample)
ES (1) ES2873181T3 (enExample)
HR (1) HRP20210891T1 (enExample)
HU (1) HUE054330T2 (enExample)
LT (1) LT2958624T (enExample)
MX (1) MX369631B (enExample)
PL (1) PL2958624T3 (enExample)
PT (1) PT2958624T (enExample)
RS (1) RS61933B1 (enExample)
SI (1) SI2958624T1 (enExample)
SM (1) SMT202100334T1 (enExample)
TW (1) TWI648050B (enExample)
WO (1) WO2014128611A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392530B (es) * 2016-03-08 2025-03-24 Priothera Ltd Aceleramiento del injerto de pacientes con trasplante
KR102948053B1 (ko) 2018-07-27 2026-04-06 프리오테라 리미티드 조혈 줄기세포 이식을 받은 환자에 있어서의 혈액 악성 종양의 재발 억제제
CN117177748A (zh) * 2020-11-04 2023-12-05 浩康生物系统公司 用于异基因造血干细胞移植的方法
EP4438037A1 (en) 2021-01-28 2024-10-02 Priothera SAS Methods of treatment with s1p receptor modulators
AU2021424131B2 (en) 2021-01-28 2026-08-13 Priothera Limited Methods of treatment with s1p receptor modulators
CA3250985A1 (en) 2022-02-16 2023-08-24 Priothera Sas CAR CELL TREATMENT METHODS IN COMBINATION WITH S1P RECEIVER MODULATORS
EP4282407A1 (en) 2022-05-27 2023-11-29 Priothera SAS Treatment of cancer with s1p receptor agonists
WO2025109119A1 (en) 2023-11-22 2025-05-30 Priothera Sas Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129573A0 (en) * 1996-11-15 2000-02-29 Baxter Int Conditioning for allogeneic stem cell transplantation
US6383481B1 (en) 1998-03-30 2002-05-07 Japan Immunoresearch Laboratories Co., Ltd. Method for transplantation of hemopoietic stem cells
JPH11343242A (ja) * 1998-03-30 1999-12-14 Otsuka Pharmaceut Co Ltd 造血幹細胞移植用剤
KR100913269B1 (ko) * 2001-09-27 2009-08-21 교린 세이야꾸 가부시키 가이샤 디아릴 황화물 유도체, 그의 염 및 이를 이용한 면역억제제
JP4571497B2 (ja) * 2002-09-19 2010-10-27 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
CN101905023B (zh) 2004-07-16 2012-07-11 杏林制药株式会社 有效的医药使用方法及与副作用发生的防御相关的方法
JP4966019B2 (ja) * 2005-01-06 2012-07-04 キッセイ薬品工業株式会社 慢性移植片対宿主症におけるドライアイの予防および治療剤
EP2566954B2 (en) 2010-05-04 2022-11-02 Yeda Research and Development Co. Ltd. Immunotherapy using redirected allogeneic cells
WO2011138398A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Dosage regimen of diaryl sulfide derivatives

Also Published As

Publication number Publication date
EP2958624B1 (en) 2021-05-12
US20160000811A1 (en) 2016-01-07
WO2014128611A1 (en) 2014-08-28
JP6441822B2 (ja) 2018-12-19
AU2014220377A1 (en) 2015-08-06
SMT202100334T1 (it) 2021-07-12
MX2015010833A (es) 2016-07-08
KR20150118149A (ko) 2015-10-21
BR112015019197A2 (pt) 2017-07-18
EP2958624A1 (en) 2015-12-30
CY1124191T1 (el) 2022-05-27
TW201511751A (zh) 2015-04-01
ES2873181T3 (es) 2021-11-03
CA2898565C (en) 2023-01-24
CN105007981B (zh) 2020-07-21
US20180153911A1 (en) 2018-06-07
MX369631B (es) 2019-11-14
CA2898565A1 (en) 2014-08-28
RS61933B1 (sr) 2021-07-30
EA201591522A1 (ru) 2016-03-31
JP6633170B2 (ja) 2020-01-22
KR102165514B1 (ko) 2020-10-15
PL2958624T3 (pl) 2021-10-04
PT2958624T (pt) 2021-06-11
EA030783B1 (ru) 2018-09-28
LT2958624T (lt) 2021-08-10
AU2014220377B2 (en) 2017-05-04
US11224604B2 (en) 2022-01-18
DK2958624T3 (da) 2021-06-07
JP2016509050A (ja) 2016-03-24
SI2958624T1 (sl) 2021-07-30
HUE054330T2 (hu) 2021-09-28
CN105007981A (zh) 2015-10-28
JP2019059748A (ja) 2019-04-18
TWI648050B (zh) 2019-01-21

Similar Documents

Publication Publication Date Title
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
JP2016509050A5 (enExample)
BR112014018485A8 (pt) Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
ECSP088762A (es) Tratamiento del dolor
BR112015006828A8 (pt) composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
HRP20131083T1 (hr) POSTUPCI PRIMJENE N-(5-terc-BUTILIZOKSAZOL-3-IL)-N&#39;-{4-[7-(2-MORFOLIN-4-ILETOKSI)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-IL]FENIL}UREE U LIJEÄŚENJU PROLIFERATIVNE BOLESTI
BR112012022187A2 (pt) tratamento de artrite reumatóide com a combinação de laquinimod e metotrexato
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
AR095197A1 (es) Combinación de un inhibidor de egfr t790m y un inhibidor de egfr para el tratamiento del cáncer pulmonar de células no pequeñas
MX369631B (es) Compuestos para usarse en el tratamiento de la enfermedad del injerto contra el huésped en pacientes de trasplante.
BR112022015727A2 (pt) Métodos para a preparação de uma quitosana reticulada, para a preparação de um sistema de liberação de fármacos, para prevenir, tratar ou melhorar um distúrbio médico e para identificar uma quitosana reticulada, quitosana reticulada, composição, enchimento de tecido mole, curativo para ferimentos ou tecido de reconstrução, nanopartículas, meio de cultura para células ou tecido biológico, uso de quitosana reticulada, e, kit
CL2015002627A1 (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
BRPI0715609A2 (pt) Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
Witzens-Harig et al. Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting
BR112015014261A8 (pt) composto de danazol, seu uso e formulação farmacêutica compreendendo este
BR112023026356A2 (pt) Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c
BR112014030288A2 (pt) composição farmacêutica
JP7245548B2 (ja) 造血幹細胞移植患者の処置
HRP20190562T1 (hr) Sastavi za liječenje zaraze srčanim crvom
Morrison et al. Non-Thermal Plasma Treatment Safely and Rapidly Eradicates MRSA from Infected Wounds
BR0317772A (pt) Método de tratamento de um distúrbio de comportamento, uso de um composto, e, agente terapêutico para um distúrbio de comportamento